Elin Pauwels

Elin Pauwels

Auto-generated profile, based on publicly available information

Elin Pauwels

Ghent University

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
PJPeggy Jacques
Peggy Jacques
SLStijn Lambrecht
Stijn Lambrecht
EVEveline Verheugen
Eveline Verheugen
EPElin Pauwels
Elin Pauwels
GKGeorge Kollias
George Kollias
DEDirk Elewaut
Dirk Elewaut
Objectives Spondyloarthritides (SpA) are characterised by both peripheral and axial arthritis. The hallmarks of peripheral SpA are the development of enthesitis, most typically of the Achilles tendon and plantar fascia, and new bone formation. This study was undertaken to unravel the mechanisms leading towards enthesitis and new bone formation in preclinical models of SpA. Results First, we demonstrated that TNFΔARE mice show typical inflammatory features highly reminiscent of SpA. The first signs of inflammation were found at the entheses. Importantly, enthesitis occurred equally in the presence or absence of mature T and B cells, underscoring the importance of stromal cells. Hind limb unloading in TNFΔARE mice significantly suppressed inflammation of the Achilles tendon compared with weight bearing controls. Erk1/2 signalling plays a crucial role in mechanotransduction-associated inflammation. Furthermore, new bone formation is strongly promoted at entheseal sites by biomechanical stress and correlates with the degree of inflammation. Conclusions These findings provide a formal proof of the concept that mechanical strain drives both entheseal inflammation and new bone formation in SpA.

22 February 2013 in Journal of Microscopy
Verified
Journal Article
Closed access
PDF file
EPE. Pauwels
E. Pauwels
DLD. VAN Loo
D. VAN Loo
PCP. Cornillie
P. Cornillie
LBL. Brabant
L. Brabant
LHL. VAN Hoorebeke
L. VAN Hoorebeke

20 October 2022 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
EPElin Pauwels
Elin Pauwels
FCFrederik Cleeren
Frederik Cleeren
TTTérence Tshibangu
Térence Tshibangu
MKMichel Koole
Michel Koole
KSKim Serdons
Kim Serdons
CDChristophe M. Deroose
Christophe M. Deroose
Chronic obstructive pulmonary disease (COPD) is a common disease in industrialised countries and responsible for a considerable morbidity and mortality. Cigarette smoking is the most important aetiological factor. The EUROSCOP trial aims at investigating the hypothesis that airway inflammation plays an important pathogenic role in the development of chronic obstructive airway disease in smokers. In cigarette smokers with poorly reversible airflow obstruction, the effect over 3 yrs of an inhaled glucocorticosteroid, budesonide 400 micrograms b.i.d., on the decline of lung function, measured as postbronchodilator forced expiratory volume in one second (FEV1), will be compared with that of placebo. The trial has been designed to detect a difference in yearly decline of at least 30 ml.year-1. The study is a parallel group, randomised, double-blind, multicentre study. Patients will be recruited from 47 centres in 12 countries in Europe. It will start with a run-in consisting of two 3 month periods. During the first 3 months, the patients will be offered a smoking cessation programme. All patients who have not stopped smoking during this period will enter the second half of the run-in where compliance with the dosage regimen will be tested. After these two periods, patients will be randomised to receive either inhaled budesonide, 400 micrograms b.i.d., or placebo for a period of 3 yrs.

1 January 2018
Verified
Journal Article
Closed access
EPElin Pauwels
Elin Pauwels
FCFrederik Cleeren
Frederik Cleeren
GBGuy Bormans
Guy Bormans
CDChristophe M. Deroose
Christophe M. Deroose

1 October 2012 in NDT & E International
Verified
Journal Article
Closed access
LBL. Brabant
L. Brabant
EPE. Pauwels
E. Pauwels
MDM. Dierick
M. Dierick
DLD. Van Loo
D. Van Loo
Matthieu BooneMatthieu Boone
Matthieu Boone
LHL. Van Hoorebeke
L. Van Hoorebeke

29 January 2020 in EJNMMI Radiopharmacy and Chemistry
Verified
Journal Article
Open access
PDF file
TTTérence Tshibangu
Térence Tshibangu
CCChristopher Cawthorne
Christopher Cawthorne
KSKim Serdons
Kim Serdons
EPElin Pauwels
Elin Pauwels
WGWilly Gsell
Willy Gsell
FCFrederik Cleeren
Frederik Cleeren
Background: Gallium-68 labeled synthetic somatostatin analogs for PET/CT imaging are the current gold standard for somatostatin receptor imaging in neuroendocrine tumor patients. Despite good imaging properties, their use in clinical practice is hampered by the low production levels of68Ga eluted from a68Ge/68Ga generator. In contrast,18F-tracers can be produced in large quantities allowing centralized production and distribution to distant PET centers. [18F]AlF-NOTA-octreotide is a promising tracer that combines a straightforward Al18F-based production procedure with excellent in vivo pharmacokinetics and specific tumor uptake, demonstrated in SSTR2 positive tumor mice. However, advancing towards clinical studies with [18F]AlF-NOTA-octreotide requires the development of an efficient automated GMP production process and additional preclinical studies are necessary to further evaluate the in vivo properties of [18F]AlF-NOTA-octreotide. In this study, we present the automated GMP production of [18F]AlF-NOTA-octreotide on the Trasis AllinOne® radio-synthesizer platform and quality control of the drug product in accordance with GMP. Further, radiometabolite studies were performed and the pharmacokinetics and biodistribution of [18F]AlF-NOTA-octreotide were assessed in healthy rats using μPET/MR.Results: The production process of [18F]AlF-NOTA-octreotide has been validated by three validation production runs and the tracer was obtained with a final batch activity of 10.8 ± 1.3 GBq at end of synthesis with a radiochemical yield of 26.1 ± 3.6% (dc), high radiochemical purity and stability (96.3 ± 0.2% up to 6 h post synthesis) and an apparent molar activity of 160.5 ± 75.3 GBq/μmol. The total synthesis time was 40 ± 3 min. Further, the quality control was successfully implemented using validated analytical procedures. Finally, [18F]AlF-NOTA-octreotide showed high in vivo stability and favorable pharmacokinetics with high and specific accumulation in SSTR2-expressing organs in rats.Conclusion: This robust and automated production process provides high batch activity of [18F]AlF-NOTA-octreotide allowing centralized production and shipment of the compound to remote PET centers. Further, the production process and quality control developed for [18F]AlF-NOTA-octreotide is easily implementable in a clinical setting and the tracer is a potential clinical alternative for somatostatin directed68Ga labeled peptides obviating the need for a68Ge/68Ga-generator. Finally, the favorable in vivo properties of [18F]AlF-NOTA-octreotide in rats, with high and specific accumulation in SSTR2 expressing organs, supports clinical translation.